There are 2 theories that attempt to elucidate the process of inflammation in patients with multiple sclerosis (MS). First, it is proposed that the disease may rely on the dysregulation of anti-inflammatory cytokines, such as interleukin-10 (IL-10) and interleukin-4 (IL-4), as well as proinflammatory cytokines such as tumor necrosis factor-α (TNFα), interleukin-2 (IL-2), interferon-γ (IFN-γ), and interleukin-1β (IL-1β). These pro- and anti-inflammatory cytokines are produced by T-helper 1 (Th-1) and Th-2 cells, respectively.^[@R1]^ Proinflammatory cytokines augment the permeability of the blood-brain barrier (BBB), allowing for the demyelization and neurodegeneration of the CNS, whereas anti-inflammatory cytokines quell the production of proinflammatory cytokines.^[@R2],[@R3]^ Second, besides the incomplete notion of Th-1/Th-2 disruption, other studies have proposed that Th-17 cells and IL-17 family members, such as IL-17A and IL-17F, are involved in the disease process. Specially, IL-17A plays a significant role in the stimulation and secretion of proinflammatory cytokines and in chronic CNS inflammation.^[@R4],[@R5]^

The development of MS may begin in individuals who are genetically susceptible.^[@R6]^ Some studies have revealed that first-degree relatives of patients with MS are a 10--25^[@R6]^ or 20--40^[@R7]^ times more likely to develop MS than the general population.

Hence, in the present study, we have proposed a schematic model for the fluctuation of pro- and anti-inflammatory cytokines by vitamin D~3~, referred to as the See-Saw model (figure e-1, [links.lww.com/NXG/A115](http://links.lww.com/NXG/A115)). In fact, we assessed the response of these interleukins to supplementation with vitamin D~3~, as well as the stabilization and balance of this scheme in all 3 groups. Ultimately, our major aim was to find an appropriate way to ameliorate the intensity of MS in afflicted patients and perhaps prevent the disease in 2 other groups via nutrigenomics, especially in first-degree relatives.

Methods {#s1}
=======

Standard protocol approvals, registrations, and patient consents {#s1-1}
----------------------------------------------------------------

This study was approved by the Ethical Committee of Tabriz University of Medical Sciences, Iran (ethical code: IR.TBZMED.REC.1395.780) and Iranian Registry of Clinical Trials (IRCT201703033655N3). Informed consent forms were obtained from all participants, and they could withdraw from the study by their own decision.

Study design and intervention {#s1-2}
-----------------------------

The study started on February 19, 2017, and ended on June 10, 2017. All randomized participants completed the trial. Twenty-five participants were randomized to each group through simple random sampling. Allocation to each group was through lottery, and random paper was concealed in draw balls ([figure 1](#F1){ref-type="fig"}), including multiple sclerosis participants (MSPs) as the first group (n = 25), first-degree relative participants (FDRPs) of patients with MS, such as son, daughter, sister, or brother as the second group (n = 25), and healthy participants (HPs) as the third group (n = 25). All groups received 50,000 IU of vitamin D~3~ orally (Zahravi Pharmaceutical Co, Tabriz, Iran) every Friday and between lunch meals for 8 weeks. Serum 25-(OH) vitamin D~3~ and mRNA expression levels of interleukins were measured before and after supplementation in all groups.

![Enrollment and selection of participants allocated to groups by simple random sampling](NG2018007302FF1){#F1}

Participants and eligibility criteria {#s1-3}
-------------------------------------

The sample size was estimated based on a previous study in Iran,^[@R8]^ with an odds ratio (OR) of 6, confidence level of 95%, and power of 80%. It was predicted that 25 persons in each group would be sufficient for the detection of changes in serum parameters and gene expression, using G-power. MSPs and FDRPs were selected from the Ardabil MS society. MSPs were diagnosed by a neurologist, according to the McDonald criteria. HPs were chosen from Ardabil University of Medical Sciences. To be included in the study, HPs were at the age of 30 ± 10 years, able to give blood samples, and willing to take part in the study. Malabsorption, taking medicines that interact with vitamin D~3~, calcium, and vitamin D~3~ supplementation in the last 30 days, gestation, and lactation were considered exclusion criteria. Demographic and disease characteristics are shown in [table 1](#T1){ref-type="table"}.

###### 

Demographic and disease characteristics

![](NG2018007302TT1)

Serum 25-(OH) vitamin D~3~ assay {#s1-4}
--------------------------------

Whole-blood samples (10 mL) were obtained from the participants before and after the trial. To separate the sera, 5 mL of the blood samples was centrifuged at 1,233*g* for 10 minutes at 4°C. Serum levels of 25-(OH) vitamin D3 were measured using electrochemiluminescence assay.

RNA extraction and cDNA synthesis {#s1-5}
---------------------------------

Five milliliters of blood samples was collected in anticoagulant EDTA tubes. Total RNA was extracted using the MN kit (MACHEREY-NAGEL, Germany), according to the manufacturer\'s instructions. Concentration, integration, and purity of RNA samples were determined by spectrometry, Nano-Drop (Thermo Scientific, Waltham, MA), and gel electrophoresis. Five micrograms of total RNA was used for cDNA synthesis with a random hexamer primer through HyperScript Reverse Transcriptase (GeneAll, South Korea) in 20 μL total reaction mixture.

Real-time PCR analysis {#s1-6}
----------------------

Real-time PCR was performed on a Roche Light cycler 96 (version: 1.1.0.1320, Germany), using primers specific for IL-6, IL-10, and IL-17A, with β-actin as a housekeeping control. Primer and probe sequences are presented in [table 2](#T2){ref-type="table"}.^[@R9][@R10][@R12]^ Real-time PCR reactions were performed in a total volume of 25 μL containing 4 μL of synthesized cDNA solution, 12.5 μL of RealQ Plus 2x Master Mix for probe (Ampliqon, Denmark), 500 nM of each forward and reverse primers, and 250 nM of the TaqMan probe. The amplification program included a prewarming step (10 minutes at 94°C), denaturation step (94°C for 15 seconds), and an annealing/extension step (60°C for 60 seconds).

###### 

Primers and probe sequences used for real-time PCR
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Outcome measures {#s1-7}
----------------

The primary outcome of the study was to identify any changes in the serum levels of 25-(OH) vitamin D~3~ or in the levels of IL-17A, IL-10, and IL-6 mRNA expression in all 3 groups after 8 weeks.

Adverse events {#s1-8}
--------------

Participants were continuously monitored for any side effects of vitamin D~3~ consumption from baseline of the study. However, no particular events were found.

Statistical analysis {#s1-9}
--------------------

Statistical analysis was performed using SPSS version 23.0 software (SPSS Inc, Chicago, IL). Data are presented using mean ± SD for numeric normal variables and frequency (percent) for categorical variables. The one-way analysis of variance (ANOVA), followed by the post hoc Tukey test, was used for group comparisons. The Paired *t* test was applied for within-group comparisons. Relative mRNA expression normalized to β-actin was calculated by the ΔΔCT method,^[@R13]^ and the fold change (FC) expression of each gene was calculated by the ratio formula (ratio = 2−^ΔΔCT^). In all analysis, *p* \< 0.05 were considered statistically significant.

Data availability
-----------------

The datasets applied and analyzed during the current study are available from the corresponding and first authors on reasonable request from any qualified investigator.

Results {#s2}
=======

The flow diagram of the study is shown in figure e-2 ([links.lww.com/NXG/A116](http://links.lww.com/NXG/A116)). Of 186 participants, 75 participants (25 per each group) were eligible to be assigned to the study intervention ([figure 1](#F1){ref-type="fig"}).

Association between vitamin D~3~ treatment and mRNA expression levels of IL-6, IL-17A, and IL-10 {#s2-1}
------------------------------------------------------------------------------------------------

### Between-group comparisons {#s2-1-1}

#### Before supplementation {#s2-1-1-1}

At baseline, the results of one-way ANOVA showed that there were differences in the mRNA expression levels of IL-6, IL-17A, and IL-10 (*p* \< 0.001 for all) among the groups, but levels of serum vitamin D~3~ (*p* = 0.063) were almost the same in all groups. The results of the pairwise comparison using the Tukey test also revealed differences between each 2 groups in IL-6 (MSPs and FDRPs: *p* \< 0.001, FDRPs and HPs: *p* \< 0.001, MSPs and HPs: *p* \< 0.001), IL-17A (MSPs and FDRPs: *p* = 0.009, FDRPs and HPs: *p* = 0.025, MSPs and HPs: *p* \< 0.001), and IL-10 (MSPs and FDRPs: *p* \< 0.001, FDRPs and HPs: *p* \< 0.001, MSPs and HPs: *p* \< 0.001) ([figures 2, A, C, and E](#F2){ref-type="fig"} and [table 3](#T3){ref-type="table"}).

![Between-group comparisons\
Effects of vitamin D~3~ supplementation on serum levels of proinflammatory and anti-inflammatory markers (n = 25 per group). (A--F) IL-6, IL-17A, and IL-10 mRNA expression levels of healthy controls (HCs), multiple sclerosis participants (MSPs), and first-degree relative participants (FDRPs). HPs (A), MSPs (B), and FDRPs (C). One-way analysis of variance, followed by the post hoc Tukey test, was used. Data were expressed as mean ± SD, and *p* \< 0.05 was regarded as statistically significant.](NG2018007302FF2){#F2}

###### 

Interleukin ΔCT and vitamin D~3~ serum levels at baseline and after 8 weeks of supplementation
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#### After supplementation {#s2-1-1-2}

After 8 weeks of supplementation with vitamin D~3~, there were differences among groups in mRNA expression levels of IL-6 (*p* \< 0.001), IL-17A (*p* \< 0.001), and IL-10 (*p* \< 0.001), as well as in the levels of serum vitamin D~3~ (*p* = 0.004). Pairwise comparisons indicated that there were differences between each 2 groups in IL-6 (MSPs and FDRPs: *p* \< 0.001, FDRPs and HPs: *p* \< 0.001, MSPs and HPs: *p* \< 0.001), IL-17A (MSPs and FDRPs: *p* = 0.022, FDRPs and HPs: *p* = 0.001, MSPs and HPs: *p* \< 0.001), IL-10 (MSPs and FDRPs: *p* = 0.005, FDRPs and HPs: *p* \< 0.001, MSPs and HPs: *p* \< 0.001), and serum vitamin D~3~ (MSPs and FDRPs: *p* = 0.022, FDRPs and HPs: *p* = 0.887, MSPs and HPs: *p* = 0.006). However, no significant differences were found in the levels of serum vitamin D3 between the FDRP and HP groups ([figures 2, B, D, and F](#F2){ref-type="fig"} and [table 3](#T3){ref-type="table"}).

### Within-group comparisons (before--after) {#s2-1-2}

The results of the paired *t* test analyses revealed that the production of proinflammatory cytokines (i.e., IL-17A and IL-6) decreased, whereas secretion of the anti-inflammatory cytokine, IL-10, increased in each group after intervention. The observed FCs in MSPs were −5.9 for IL-17A, (*p* = 0.014), −5.6 for IL-6 (*p* = 0.003), and 6.2 for IL-10 (*p* = 0.005). The FCs in FDRPs were −5.2 for IL-17A (*p* = 0.006), −5.5 for IL-6 (*p* = 0.002), and 4.6 for IL-10 (*p* \< 0.001). In HPs, the FCs were −4.2 for IL-17A (*p* = 0.012), −5.1 for IL-6 (*p* \< 0.001), and 5.2 for IL-10 (*p* \< 0.001) ([figures 3, A--C](#F3){ref-type="fig"} and [table 3](#T3){ref-type="table"}). In addition, the ratio of pro- to anti-inflammatory cytokines, including the ratio of IL-17A to IL-10 and IL-6 to IL-10, in each group showed that there were differences within the groups (MSPs, *p* \< 0.001; FDRPs, *p* \< 0.001; HPs, *p* \< 0.001, [figure 3, D and E](#F3){ref-type="fig"}).

![Within-group comparisons (before--after)\
Effects of vitamin D~3~ on serum levels of proinflammatory and anti-inflammatory markers (n = 25 per group) (A--C) and the ratio of pro-to anti-inflammatory cytokines (D and E). IL-6, IL-17A, and IL-10 mRNA expression levels of healthy participants, patients with MS, and first-degree relatives. Paired *t* test analysis was used. Data were expressed as mean ± SD. \**p* \< 0.05 was regarded as statistically significant.](NG2018007302FF3){#F3}

Discussion {#s3}
==========

With respect to the role of vitamin D~3~ in the immune system and gene expression, we proposed a schematic balance for fluctuations of pro- (IL-17A and IL-6) and anti-inflammatory (IL-10) cytokines by vitamin D~3~ that we refer to as the See-Saw model.

In the present trial, 88% of MSPs, 84% of FDRPs, and 80% of HPs showed a positive response after 8 weeks supplementation with 50,000 IU vitamin D~3~. There were no differences in serum vitamin D~3~ levels among the groups at baseline. This finding is similar to the results of other studies.^[@R14],[@R15]^ However, our finding does not conform with that of other studies, which indicated that serum levels of vitamin D~3~ in MSPs were lower than those in HPs.^[@R16],[@R17]^ This contradiction may be justified by several reasons, including economic conditions, clothing, inappropriate food habits, and above all, weather conditions and geographical location (the mountainous weather of Northwest of Iran with higher latitude and lower temperature). These may all cause lower exposure to sunlight and consequent insufficiency of serum vitamin D~3~. Several studies indicate that vitamin D~3~ deficiency is a common phenomenon among patients with MS with neuroinflammatory lesions.^[@R18]^ In addition, numerous studies have demonstrated the effects of 1, 25-(OH)~2~ vitamin D~3~ on antigen-presenting cell (APC) function and T-cell responses. Vitamin D~3~ directly increases the expression level of vitamin D receptor (VDR), especially after bioactivation on T cells.^[@R19]^ Duan et al.^[@R20]^ reported that VDR is the active form of vitamin D receptor and is widely expressed in the brain. Evidence suggests that VDRs and vitamin D are key molecules for the development of the nervous system, and they can reduce anxiety and increase the production of neurotrophic factors.

1,25-(OH)~2~ vitamin D~3~ can take part in the activation or repression of gene transcription and expression through direct interaction with VDR/retinoid X receptor (RXR). By this mechanism, 1,25-(OH)~2~ vitamin D~3~ is able to bind directly to specific DNA sequences called vitamin D response elements (VDREs) in target genes.^[@R21]^

Our findings indicate that administration of vitamin D~3~ decreased the mRNA expression levels of IL-17A and IL-6 and increased the mRNA expression level of IL-10 in all 3 groups. Of 25 participations in each group, we observed downregulation of IL-17A in 76% of MSPs, 80% of FDRPs, and 80% of HPs; we also observed that downregulation of IL-6 in 80% of MSPs, 80% of FDRPs, and 84% of HPs occurred after 8-week treatment with 50,000 IU vitamin D~3~. In addition, 80% of MSPs, 88% of FDRPs, and 84% of HPs showed upregulation of IL-10.

IL-17A is produced by Th17 cells, which have a major function in the progression of immune system disorders including MS.^[@R22]^ Luchtman et al. demonstrated an increase in the secretion of IL-17 in the periphery and in the CNS of patients with MS. IL-17 can lead to increased CCL2, IL-6, and IL-8 secretion. In addition, IL-17 production also results in the formation of reactive oxygen species.^[@R23]^ Upregulation of IL-6 occurs during neuroinflammation of the CNS and leads to neuronal damage, especially in axons.^[@R24]^ Furthermore, the presence of transforming growth factor-β (TGF-β) and IL-6 stimulates T-cell differentiation into Th-17 cells, which subsequently increases the level of IL-17A secretion.^[@R8],[@R24]^ IL-6 plays a key role in MS development in 2 ways: by increasing IL-17 and IL-22 secretion and through the upregulation of CCR6 expression on activated myelin-specific T cells. Therefore, it seems that IL-17A and IL-6 act as agonists through these pathways.^[@R25],[@R26]^ Da Costa et al.^[@R27]^ reported that IL-6 and IL-17A levels directly correlated with neurologic disabilities in patients with MS. Moreover, 1,25-(OH)~2~ vitamin D~3~ decreases the secretion of proinflammatory cytokines in vitro. Naghavi Gargari et al.^[@R8]^ indicated a positive association between the mRNA expression of IL-6 and IL-17A. Supplementation of 1,25-(OH)~2~ vitamin D~3~ inhibits IL-17A production in T cells of patients with MS.^[@R28]^ In fact, vitamin D~3~ administration can ameliorate MS disease through to downregulation of IL-17A and IL-6. On the other hand, a pivotal role of anti-inflammatory cytokines, especially IL-10, stimulated by vitamin D~3~, has been established in the suppression of T-cell activation through macrophages. Therefore, the arrest of IL-10 production may exacerbate inflammation.^[@R29],[@R30]^ Thereby, vitamin D~3~ supplementation can increase IL-10 by T cells and reduce the production of IL-6 and IL-17 in both patient and control groups.^[@R31]^

Nevertheless, in several studies, contradictory results have also been reported. For instance, Fujita et al. and Niino et al. have both shown that 1,25-(OH)~2~ vitamin D~3~ can downregulate the production of IL-10.^[@R32],[@R33]^. In addition, studies by Naghavi Gargari et al. and Smolders et al. have demonstrated the upregulation of IL-6 and IL-17A by vitamin D.^[@R8],[@R34]^ Meanwhile, Yao et al.^[@R35]^ have shown that IL-6 has anti- and pro-inflammatory effects and that it can be secreted from various cell types, including lymphocytes, macrophages, and monocytes. Multiple factors, including the variety of cell types studied, duration and dosage of 1,25(OH)~2~ vitamin D~3~ treatment, type of samples, genetic inheritance of patients, and polymorphisms in VDR genes, have all been proposed to account for these contradictory findings as reported in several studies.^[@R8],[@R14],[@R29],[@R36]^

In this study, we also compared the ratio of pro- to anti-inflammatory cytokines (IL-17A:IL-10 and IL-6:IL-10). In all groups, both ratios were improved, but the most significant changes occurred in MSPs. In addition, the changes in the ratio of IL-6:IL-10 were found to be more important than the changes in the ratio of IL-17A:IL-10. Therefore, these results may confirm 2 points: First, vitamin D~3~ reduces the gene expression levels of IL-6 and IL-17A. The expression level of IL-6 decreases subsequent to the reduction in IL-17A expression, which is why the ratio of in IL-6:IL10 was more tangible. Second, increased expression of IL-10 had a negative feedback effect on the expression levels of IL-17A and IL-6.

To prove the accuracy of the proposed schematic (See-Saw model), the sample size should be increased in each group. In addition, a blank control group (out of the restricted criteria) should be more defined. In this state, a placebo would be administered to determine the actual effects of vitamin D~3~ on the expression levels of genes. Overall, the results suggest that long-term supplementation with a lower daily dosage may be beneficial. Furthermore, participants should be assessed at the midpoint of the study to determine the temporal effect of vitamin D~3~ supplementation. A reliable questionnaire should also be devised and used for the effect of vitamin D~3~ supplements on the behavioral and mental performance of the participants before and after the intervention. The present study and many other similar ones only examined the mRNA expression levels of these cytokines; however, an analysis of cytokine protein expression would be useful to confirm the effect of vitamin D~3~. In addition, epigenetic studies may be useful to address some of the contradictions presented by other studies. Epigenetics refers to the modification of gene expression and changes in chromatin structure without alteration of the DNA sequence.^[@R37]^ Recent studies suggest that interactions between environmental factors and epigenetic parameters are an underlying cause of MS.

Finally, we determined that upregulation of IL-10 and downregulation of IL-17A and IL-6 occur at sufficient serum levels of vitamin D~3~. These features were more noticeable in MSPs. As mentioned earlier, IL-17A and IL-6 augment the production of each other. Sufficient serum levels of vitamin D~3~ result in the production of IL-10 and have a negative feedback effect on the expression levels of IL-17A and IL-6. Stabilization and proper balance of the schematic See-Saw model by sufficient levels of vitamin D~3~ seem to offer a feasible method for protection from MS by dietary modifications.
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